Nxera Pharma receives JPY 2,793m dividend from UK subsidiary

Nxera Pharma Co. Ltd. announced on December 8, 2025, the receipt of JPY 2,793 million in dividends from its consolidated subsidiary, Nxera Pharma UK Limited. The total dividend distributed by the UK subsidiary was JPY 8,193 million, with the receipt date for Nxera Pharma being November 26, 2025. This transaction is considered a material event under Japanese financial regulations.

The dividend income of JPY 2,793 million will be recorded as non-operating income in Nxera Pharma's non-consolidated financial statements for the fiscal year ending December 31, 2025. However, as the dividends are from a consolidated subsidiary, there will be no impact on the company's consolidated financial results for the same period.

Nxera Pharma is a technology-driven biopharmaceutical company focused on developing and commercializing new specialty medicines to address unmet patient needs globally. The company leverages its NxWave™ discovery platform to advance a pipeline of over 30 programs, with a strong focus on areas such as obesity, metabolic disorders, neurology, neuropsychiatry, immunology, and inflammation.